Automated Cough Analysis with Convolutional Recurrent Neural Network.

Chronic cough is associated with several respiratory diseases and is a significant burden on physical, social, and psychological health. Non-invasive, real-time, continuous, and quantitative monitoring tools are highly desired to assess cough severity, the effectiveness of treatment, and monitor disease progression in clinical practice and research. There are currently limited tools to quantitatively measure spontaneous coughs in daily living settings in clinical trials and in clinical practice.

Management of adult mechanically ventilated patients: A UK-wide survey.

Background: Mechanical ventilation is a common and often lifesaving intervention that is utilised in intensive care. However, the practices can vary between centres. Through this national survey we aim to gain more information about different strategies adopted across the UK.

Auditory areas are recruited for naturalistic visual meaning in early deaf people.

Congenital deafness enhances responses of auditory cortices to non-auditory tasks, yet the nature of the reorganization is not well understood. Here, naturalistic stimuli are used to induce neural synchrony across early deaf and hearing individuals. Participants watch a silent animated film in an intact version and three versions with gradually distorted meaning.

Effect of benralizumab on inflammation in skin after intradermal allergen challenge in patients with moderate-to-severe atopic dermatitis.

Background: Atopic dermatitis (AD) is a skin barrier dysfunction characterized by tissue eosinophilia.

Objective: In patients with AD, we evaluated the effect of eosinophil depletion with benralizumab on markers of inflammation in skin after intradermal allergen challenge.

Methods: A total of 20 patients with moderate-to-severe AD completed a randomized, double-blind, placebo-controlled parallel-group study comparing 3 doses of benralizumab (30 mg each) administered subcutaneously every 4 weeks (n = 9) with placebo (n = 11).

Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial.

Background: Benralizumab induces rapid and near-complete depletion of eosinophils from blood and lung tissue. We investigated whether benralizumab could attenuate the allergen-induced late asthmatic response (LAR) in participants with allergic asthma.

Methods: Participants with allergic asthma who demonstrated increased sputum eosinophils and LAR at screening were randomised to benralizumab 30 mg or matched placebo given every 4 weeks for 8 weeks (3 doses).